Table 2 Base case results
| Ceritinib (450 mg) | Crizotinib | Ceritinib vs. Crizotinib | |
|---|---|---|---|
| Cost (USD) | |||
| Drug and drug administration costs, initial treatment | 82,215 | 82,623 | − 408 |
| Drug and drug administration costs, post-progression treatment | 10,392 | 9,921 | 471 |
| Treatment associated adverse event costs | 1,982 | 1,197 | 785 |
| Medical costs | 62,992 | 56,683 | 6,309 |
| Total costs | 157,581 | 150,424 | 7,157 |
| Effectiveness | |||
| Total QALYs | 3.22 | 2.68 | 0.54 |
| Total LYs | 4.51 | 3.85 | 0.66 |
| Incremental cost-effectiveness ratio (ICER) (USD) | |||
| Incremental cost per QALY gained | 13,343 | ||
| Incremental cost per LY gained | 10,794 | ||
